Metacrine is a biotech company developing innovative therapeutics for metabolic diseases. The company is led by an experienced management team and backed by leading institutional investors. Founded in 2015, Metacrine’s initial technology was licensed from the laboratory of Dr. Ronald Evans, a world leader in nuclear hormone receptors and Howard Hughes Medical Institute Investigator at the Salk Institute. The current focus of the company is to develop novel therapeutics for significant metabolic diseases such as type 2 diabetes and non-alcoholic steatohepatitis (NASH). There are over 30 million type 2 diabetics in the United States and despite numerous available drug classes, close to 50% of patients are unable to achieve target HbA1c levels and glucose control. Similarly, non-alcoholic steatohepatitis (NASH) is reaching epidemic proportions in the US and worldwide, with nearly 20% of Americans having some stage of fatty liver disease. Currently, there is no approved therapy for NASH. Metacrine will leverage two mechanistically distinct programs to target type 2 diabetes, NASH and other metabolic diseases and liver disorders.
Show more
HQSan Diego, US
Size (employees)29 (est)
Metacrine was founded in 2015 and is headquartered in San Diego, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Metacrine

Ken Song

Ken Song

President and Chief Executive Officer
Trisha Millican

Trisha Millican

Hubert Chen

Hubert Chen

Chief Medical Officer
Nicholas Smith

Nicholas Smith

Senior Vice President, Chemistry
Eric Bischoff

Eric Bischoff

Vice President, Development and Operations
Karl Cremer

Karl Cremer

Vice President, Clinical Operations
Show more

Metacrine Office Locations

Metacrine has an office in San Diego
San Diego, (HQ)
301 12780 El Camino Real
Show all (1)
Report incorrect company information

Metacrine Financials and Metrics

Summary Metrics

Founding Date


Metacrine total Funding

$123 m

Metacrine latest funding size

$65 m

Time since last funding

6 months ago

Metacrine investors

Metacrine's latest funding round in June 2018 was reported to be $65 m. In total, Metacrine has raised $123 m
View all funding rounds
Report incorrect company information

Metacrine Blogs

MET409 a potent, non-bile acid sustained FXR agonist, shows rapid disease reversal in a diet-induced obese model of biopsy-confirmed NASH

Download PDF The post MET409 a potent, non-bile acid sustained FXR agonist, shows rapid disease reversal in a diet-induced obese model of biopsy-confirmed NASH appeared first on Metacrine.

Treatment response of murine sclerosing cholangitis to systemic versus intestinal FXR agonists segregates with their effects on hepatic pro-inflammatory cytokine production

Authors & affiliations: Tiffany Shi1, Louis Matuschek1, Celine S. Lages1, Ramesh Kudira1, Mary Mullen1, Alvaro Ortiz2, Kyoung-Jin Lee2,Douglas Zook2, Brandee Wagner2, Alexander Miethke1 1Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincin…

Metacrine to Present Rapid Efficacy of MET409 in a NASH Mouse Model at The Liver Meeting 2018

SAN DIEGO, November 5, 2018 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, will present data showing rapid efficacy of MET409, a potent, systemic and sustained non-bile aci…

DMPK Scientist

We are looking for a motivated, flexible, highly productive individual who is seeking a dynamic fast-paced biotechnology environment. This individual will report to the Head of DMPK and will interact extensively with the research and development team. Key Responsibilities Design and execute all aspe…

Accounting Manager

Job Description Metacrine, Inc. is seeking an Accounting Manager to join our team. This position reports directly to the Assistant Controller. The Accounting Manager will coordinate and help execute the accounting functions. The ideal candidate will be highly motivated, detailed oriented self-starte…

Metacrine Appoints Hubert Chen, M.D. as Chief Medical Officer and Andrew Guggenhime to the Board of Directors

SAN DIEGO, September 6, 2018 – Metacrine, Inc., a biotechnology company developing therapies to benefit patients with liver and gastrointestinal diseases (GI), today announced the appointment of Hubert C. Chen, M.D., as Chief Medical Officer, and Andrew Guggenhime as a director of the company. Dr. C…
Show more

Metacrine Company Life and Culture

Report incorrect company information

Metacrine Frequently Asked Questions

  • When was Metacrine founded?

    Metacrine was founded in 2015.

  • Who are Metacrine key executives?

    Metacrine's key executives are Ken Song, Trisha Millican and Hubert Chen.

  • How many employees does Metacrine have?

    Metacrine has 29 employees.

  • Who are Metacrine competitors?

    Competitors of Metacrine include Tizona Therapeutics, Evelo Therapeutics and Yumanity Therapeutics.

  • Where is Metacrine headquarters?

    Metacrine headquarters is located at 301 12780 El Camino Real, San Diego.

  • Where are Metacrine offices?

    Metacrine has an office in San Diego.

  • How many offices does Metacrine have?

    Metacrine has 1 office.